MoonLake Immunotherapeutics - Class A Ordinary Shares MLTX 深 沪
已收盘 11-14 16:00:00 美东时间
12.77
+0.210
+1.67%
华盛通- 最 高12.965
- 今 开12.35
- 成交量 141.36万股
- 最 低 12.21
- 昨 收 12.56
- 总市值 8.11亿
- 52周最高 62.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.95
- 委 比 -92.66%
- 总股本 6350.14万
- 历史最高 64.98
- 量 比 0.62
- 振 幅 6.01%
- 历史最低 4.25
- 每 手 1
- 风险率 14.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MoonLake Reports Clinical Data From Sonelokimab Studies, Nanobody Drug Shows Results In Multiple Trials For Rare Skin Diseases, Eyes FDA Filing In 2026
MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results
11-05 20:21
MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.88) by 25.14 percent. This is a 96.43 percent decrease over losses of $(0.56) per share from the
11-05 20:13
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Citigroup Downgrades MoonLake to Sell, Maintains Price Target to $5
Citigroup analyst Samantha Semenkow downgrades MoonLake (NASDAQ:MLTX) from Neutral to Sell and maintains the price target from $5 to $5.
10-30 03:54
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MapLight Therapeutics completed its initial public offering, raising $296.3 million through the sale of 16.96 million shares at $17 each, including underwriters' option exercise. The shares, trading under "MPLT" on the Nasdaq, began on October 27. Morgan Stanley, Jefferies, Leerink Partners, and Stifel led the offering. MapLight focuses on treatments for CNS disorders like schizophrenia and Alzheimer's disease psychosis, with its lead candidate i...
10-29 13:06
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
The most oversold stocks in the health care sector presents an opportunity to b...
10-06 18:23
HC Wainwright & Co. Downgrades MoonLake to Neutral
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades MoonLake (NASDAQ:MLTX) from Buy to Neutral.
10-02 18:43
美股异动 | 医药股延续涨势！阿斯利康涨近7%，葛兰素史克涨超4%
医药股延续涨势！阿斯利康涨近7%，葛兰素史克涨超4%；金价持续冲高！泛美白银、哈莫尼黄金涨约3%；美国锂业公司LAC涨超18%>>
10-01 21:53
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
